|
US5443956A
(en)
|
1985-01-29 |
1995-08-22 |
Oncogene Science, Inc. |
Detection, quantitation and classification of RAS proteins in body fluids and tissues
|
|
GB9103974D0
(en)
|
1991-02-26 |
1991-04-10 |
Norsk Hydro As |
Therapeutically useful peptides or peptide fragments
|
|
US9340577B2
(en)
|
1992-08-07 |
2016-05-17 |
Epimmune Inc. |
HLA binding motifs and peptides and their uses
|
|
CN1225590A
(zh)
|
1996-03-11 |
1999-08-11 |
埃皮曼尼公司 |
对hla分子结合亲和力提高的肽
|
|
US20020164318A1
(en)
|
1997-02-18 |
2002-11-07 |
Houghton Alan N. |
Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
|
|
WO1999063945A2
(en)
|
1998-06-12 |
1999-12-16 |
Sloan-Kettering Institute For Cancer Research |
Vaccination strategy to prevent and treat cancers
|
|
EP1230268B1
(en)
|
1999-11-18 |
2009-10-14 |
Pharmexa Inc. |
Heteroclitic analogs of class i epitopes
|
|
US6602510B1
(en)
|
2000-04-05 |
2003-08-05 |
Epimmune Inc. |
HLA class I A2 tumor associated antigen peptides and vaccine compositions
|
|
US20030224036A1
(en)
|
1999-12-13 |
2003-12-04 |
Fikes John D |
Hla class I a2 tumor associated antigen peptides and vaccine compositions
|
|
US20070098776A1
(en)
|
1999-12-13 |
2007-05-03 |
Fikes John D |
HLA class I A2 tumor associated antigen peptides and vaccine compositions
|
|
JP2003521245A
(ja)
|
1999-12-21 |
2003-07-15 |
エピミューン， インコーポレイテッド |
ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
|
|
FR2812087B1
(fr)
|
2000-07-21 |
2007-05-11 |
Inst Nat Sante Rech Med |
Procede de criblage de peptides utilisables en immunotherapie
|
|
CA2438505A1
(en)
|
2001-02-14 |
2002-09-12 |
Genzyme Corporation |
Altered peptide ligands
|
|
WO2003008537A2
(en)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
EP1495322A4
(en)
|
2002-04-05 |
2006-09-06 |
Epimmune Inc |
HETEROKLITIC ANALOGUES AND ASSOCIATED METHODS
|
|
AU2003295328A1
(en)
|
2002-10-02 |
2004-04-23 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20070054262A1
(en)
|
2003-03-28 |
2007-03-08 |
Baker Denise M |
Methods of identifying optimal variants of peptide epitopes
|
|
PT1620456E
(pt)
|
2003-04-18 |
2014-04-15 |
Biotech Synergy Inc |
Péptidos antigénicos hla-a2 associados a tumor e suas composições
|
|
WO2005042698A2
(en)
|
2003-10-23 |
2005-05-12 |
Pecos Labs, Inc. |
T cell epitopes useful in a hepatitis c virus vaccine and as diagnostic tools and methods for identifying same
|
|
CA2548135C
(en)
|
2003-12-01 |
2014-04-22 |
Sloan-Kettering Institute For Cancer Research |
Synthetic hla binding peptide analogues and uses thereof
|
|
CA2566506A1
(en)
|
2004-06-01 |
2005-12-15 |
Innogenetics N.V. |
Peptides for inducing a ctl and/or htl response to hepatitis c virus
|
|
WO2006120038A2
(en)
|
2005-05-09 |
2006-11-16 |
Vaxon Biotech |
Use of native peptides and their optimized derivatives for vaccination
|
|
EP1882187A4
(en)
|
2005-05-12 |
2010-10-20 |
Merck Sharp & Dohme |
SYSTEM AND METHOD FOR THE AUTOMATED SELECTION OF T-CELL EPITOPES
|
|
NZ564359A
(en)
|
2005-06-17 |
2011-09-30 |
Mannkind Corp |
Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
|
|
EP1951281B1
(en)
|
2005-10-17 |
2015-04-15 |
Sloan Kettering Institute For Cancer Research |
Wt1 hla class ii-binding peptides and compositions and methods comprising same
|
|
CA2634480C
(en)
|
2005-12-23 |
2013-10-15 |
Vaxon Biotech |
Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof
|
|
WO2008010010A1
(en)
|
2006-07-12 |
2008-01-24 |
Vaxon Biotech |
Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
|
|
WO2009002418A2
(en)
|
2007-06-21 |
2008-12-31 |
Merck & Co., Inc. |
T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
|
|
JP2011502484A
(ja)
|
2007-11-01 |
2011-01-27 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
|
|
WO2010018136A1
(en)
|
2008-08-12 |
2010-02-18 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
|
|
RS53782B1
(sr)
|
2008-10-01 |
2015-06-30 |
Immatics Biotechnologies Gmbh |
Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
|
|
JP5756792B2
(ja)
|
2009-04-02 |
2015-07-29 |
ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ |
免疫療法のための潜在性ｈｌａ−ａ２４エピトープの同定、最適化及び使用
|
|
ES2533228T3
(es)
|
2009-06-09 |
2015-04-08 |
Vaxon Biotech |
Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia
|
|
GB201006360D0
(en)
|
2010-04-16 |
2010-06-02 |
Immatics Biotechnologies Gmbh |
Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
|
|
EP2576614A4
(en)
|
2010-05-24 |
2013-11-13 |
Phosimmune Inc |
CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
|
|
PL3892295T3
(pl)
|
2011-05-24 |
2023-07-24 |
BioNTech SE |
Zindywidualizowane szczepionki przeciwnowotworowe
|
|
EP2983702A2
(en)
|
2013-04-07 |
2016-02-17 |
The Broad Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
JP6781403B2
(ja)
|
2013-12-09 |
2020-11-04 |
タルゴバックス エーエスエー |
ペプチド混合物
|
|
US10238741B2
(en)
|
2014-10-10 |
2019-03-26 |
The Trustees Of Columbia University In The City Of New York |
Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
|
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
BR112017022845A2
(pt)
|
2015-04-23 |
2018-07-17 |
Nantomics, Llc |
neoepítopos de câncer
|
|
EA201792501A1
(ru)
|
2015-05-13 |
2018-10-31 |
Эйдженус Инк. |
Вакцины для лечения и профилактики рака
|
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
JP2019513373A
(ja)
|
2016-03-31 |
2019-05-30 |
ネオン セラピューティクス， インコーポレイテッド |
ネオ抗原およびその使用方法
|
|
US11296398B2
(en)
|
2016-10-06 |
2022-04-05 |
Avery Dennison Retail Information Services Llc |
Methods for creating RFID tags based on flexible antenna materials
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
TWI728201B
(zh)
|
2016-11-01 |
2021-05-21 |
丹麥商諾佛 儂迪克股份有限公司 |
耐受性ｄｎａ疫苗
|
|
WO2018094569A1
(zh)
|
2016-11-22 |
2018-05-31 |
深圳华大基因研究院 |
多肽及其应用
|
|
WO2018102585A1
(en)
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
|
|
CA3035591A1
(en)
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
|
|
BR112019015797A2
(pt)
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
US11965892B2
(en)
|
2017-02-12 |
2024-04-23 |
Biontech Us Inc. |
HLA-based methods and compositions and uses thereof
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
CA3058807A1
(en)
|
2017-04-03 |
2018-10-11 |
Biontech Us Inc. |
Protein antigens and uses thereof
|
|
WO2018188730A1
(en)
|
2017-04-11 |
2018-10-18 |
Biontech Rna Pharmaceuticals Gmbh |
Rna for treatment of autoimmune diseases
|
|
EP3400959A1
(en)
|
2017-05-09 |
2018-11-14 |
Vaxon Biotech |
Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a hla-a*0201-positive patient having a non-immunogenic tumor expressing tert
|
|
AU2018366131A1
(en)
|
2017-11-08 |
2020-05-28 |
Advaxis, Inc. |
Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
AU2019275072A1
(en)
|
2018-05-23 |
2021-01-21 |
Seattle Project Corp. |
Shared antigens
|
|
MX2020014243A
(es)
|
2018-06-19 |
2021-05-12 |
Biontech Us Inc |
Neoantigenos y usos de los mismos.
|
|
CN112584852A
(zh)
|
2018-06-19 |
2021-03-30 |
百欧恩泰美国公司 |
新抗原及其用途
|
|
AU2019293244B2
(en)
|
2018-06-27 |
2026-04-02 |
Modernatx, Inc. |
Personalized cancer vaccine epitope selection
|
|
WO2020020444A1
(en)
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
JP2021533777A
(ja)
*
|
2018-08-16 |
2021-12-09 |
ビオンテック ユーエス インコーポレイテッド |
Ｔ細胞受容体構築物およびその使用
|
|
US20200069782A1
(en)
|
2018-08-28 |
2020-03-05 |
CeCaVa GmbH & Co. KG |
Methods for selecting tumor-specific neoantigens
|
|
WO2020154617A1
(en)
*
|
2019-01-25 |
2020-07-30 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting mutant ras
|
|
WO2020252039A1
(en)
|
2019-06-12 |
2020-12-17 |
Biontech Us Inc. |
Neoantigen compositions and uses thereof
|
|
CN112110995A
(zh)
|
2019-06-19 |
2020-12-22 |
上海交通大学医学院 |
肿瘤新抗原多肽及其用途
|
|
CA3146591A1
(en)
*
|
2019-09-20 |
2021-03-25 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides and methods of use thereof
|
|
US12453774B2
(en)
|
2019-11-07 |
2025-10-28 |
Genoimmune Therapeutics Co., Ltd. |
Tumor immunotherapy polypeptide and application thereof
|
|
JP2023523664A
(ja)
|
2019-11-18 |
2023-06-07 |
エピヴァックス セラピューティクス インコーポレイテッド |
改善されたネオエピトープワクチン及びがんを治療するための方法
|
|
US11977057B2
(en)
|
2020-06-13 |
2024-05-07 |
Complete Omics International Inc. |
Method and system for neoantigen analysis
|
|
CA3189269A1
(en)
|
2020-08-13 |
2022-02-17 |
Vikram JUNEJA |
Ras neoantigens and uses thereof
|
|
US11161892B1
(en)
|
2020-12-07 |
2021-11-02 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
US11058751B1
(en)
*
|
2020-11-20 |
2021-07-13 |
Think Therapeutics, Inc. |
Compositions for optimized RAS peptide vaccines
|
|
JP2024501482A
(ja)
|
2020-12-14 |
2024-01-12 |
ビオンテック ユーエス インコーポレイテッド |
がん免疫療法のための組織特異的抗原
|
|
US12275766B2
(en)
*
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
CN116867799A
(zh)
|
2021-02-10 |
2023-10-10 |
上海吉倍生物技术有限公司 |
Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
|
|
WO2022180219A1
(en)
|
2021-02-25 |
2022-09-01 |
Kosmatopoulos Kostantinos Kostas |
Optimized vaccine to elicit a t cell immunity against sars-cov-2
|
|
US11464842B1
(en)
*
|
2021-04-28 |
2022-10-11 |
Think Therapeutics, Inc. |
Compositions and method for optimized peptide vaccines using residue optimization
|
|
WO2023170535A2
(en)
|
2022-03-04 |
2023-09-14 |
Proof Diagnostics, Inc. |
Novel nucleic acid-guided nucleases and use thereof
|
|
TW202402798A
(zh)
|
2022-05-23 |
2024-01-16 |
美商艾費尼Ｔ醫療公司 |
對新抗原具特異性之結合蛋白與工程化細胞及其用途
|